Sood AK

No ORCID on file · 17 papers in corpus · active 2008-2025
2025
Cancer research ·doi:10.1158/0008-5472.can-25-0654

Subunits of the SWI/SNF chromatin remodeling complex are altered in ∼20% of human cancers. Exemplifying the alterations is the ARID1A mutation that occurs in ∼50% of ovarian clear-cell carcinoma (OCCC), a disease with limited therapeutic op…

2024
Gynecologic Oncology ·doi:10.1016/j.ygyno.2024.08.010

ObjectiveHigh-grade (HGOC) and low-grade ovarian carcinoma (LGOC) are distinct malignancies with different biological features, treatment paradigms, and life expectancies. However, differences in quality of life (QOL), sleep, and depressive…

2021
Carcinogenesis ·doi:10.1093/carcin/bgab043

Recently, ovarian cancer research has evolved considerably because of the emerging recognition that rather than a single disease, ovarian carcinomas comprise several different histotypes that vary by etiologic origin, risk factors, molecula…

2020
Molecular cancer therapeutics ·doi:10.1158/1535-7163.mct-19-1026

Abnormal activity of human prolactin (PRL) and its membrane-associated receptor (PRLR) contributes to the progression of uterine carcinoma. However, the underlying mechanisms are not well understood, and current means of targeting the PRL/P…

2020
Anesthesia and analgesia ·doi:10.1213/ane.0000000000004767

One of the most prevalent symptoms after major surgery is pain. When postoperative pain treatment is unsatisfactory, it can lead to poor surgical recovery, decreased quality of life, and increased health care costs. Current analgesics, sing…

2019
Clinical chemistry ·doi:10.1373/clinchem.2018.299289

BackgroundAccurate tissue diagnosis during ovarian cancer surgery is critical to maximize cancer excision and define treatment options. Yet, current methods for intraoperative tissue evaluation can be time intensive and subjective. We have …

2019
EBioMedicine ·doi:10.1016/j.ebiom.2018.11.045

BackgroundInflammatory mediator prostaglandin E2-prostaglandin E2 receptor EP3 (PTGER3) signaling is critical for tumor-associated angiogenesis, tumor growth, and chemoresistance. However, the mechanism underlying these effects in ovarian c…

2018
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society ·doi:10.1097/igc.0000000000001329

ObjectiveEstablishing an accurate histologic diagnosis is essential for determining the appropriate course of therapy for ovarian cancer. This study sought to investigate and describe nonovarian cancer pathologies discovered during the syst…

2016
Nature reviews. Disease primers ·doi:10.1038/nrdp.2016.61

Ovarian cancer is not a single disease and can be subdivided into at least five different histological subtypes that have different identifiable risk factors, cells of origin, molecular compositions, clinical features and treatments. Ovaria…

2013
Nature reviews. Clinical oncology ·doi:10.1038/nrclinonc.2013.5

The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics, despite prolific drug development. Robust clinical investigation, particularl…

2011
PloS one ·doi:10.1371/journal.pone.0021121

Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes. Despite this, patients with these tumors are treated in a simi…

2011
Nature reviews. Cancer ·doi:10.1038/nrc3144

There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international grou…

2010
Cancer ·doi:10.1002/cncr.25299

BackgroundMultiple alterations in circadian rhythms have been observed in cancer patients, including the diurnal rhythm of the adrenal hormone cortisol. Diurnal cortisol alterations have been associated with cancer-related physiological pro…

2010
Hormones & cancer ·doi:10.1007/s12672-010-0054-2

Multiple genetic alterations play a role in the pathogenesis of ovarian cancer. Although many key proteins and pathways involved in ovarian carcinogenesis and metastasis have been discovered, knowledge of the early steps leading to malignan…

2010
Cancer biomarkers : section A of Disease markers ·doi:10.3233/cbm-2011-0212

Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy despite several decades of progress in diagnosis and treatment. Taking advantage of the robust development of discovery and utility of prognostic biomarkers, c…

2009
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-08-2525

PurposeThe effects of reproductive hormones on ovarian cancer growth are not well understood. Here, we examined the effects of estrous cycle variation and specific reproductive hormones on ovarian cancer growth.Experimental designWe investi…

2008
Brain, behavior, and immunity ·doi:10.1016/j.bbi.2007.12.012

The adaptive immune response of ovarian cancer patients has been linked to survival, and is known to be impaired in the tumor microenvironment. Little is known about relationships between biobehavioral factors such as depressed mood and anx…